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INTRODUCTION
Bone is the most rigid tissue in the human body. Yet, it is the 
most dynamic and ever‑changing tissue apart from blood. From 
birth until around age 20 years, the bone grows and stores up its 
calcium reserve. At the same time and under all circumstances, 
every bone unit is undergoing continuous changes of breakdown 
and restoration. These rapid, continuous changes are required for 
the control of calcium metabolism and to maintain the healthy 
state of the bone. Special cells called osteoblasts are responsible 
for the build‑up of the bone unit, while other special cells called 
osteoclasts are responsible for the breakdown. Build‑up and 
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ABSTRACT
Osteoporosis is an aging problem. The declining bone mineral density (BMD) enhances the chances of fractures during minor falls. 
Effective pharmaceuticals are available for a rapid improvement of BMD. However, hormonal treatment gives serious complications, 
and bisphosphonates may lead to odd fractures of long bones, resulting from excessive rigidity of the cortical components. Many 
medicinal herbs used in Traditional Chinese Medicine, known as kidney tonics, have been tested for their effects on bone metabolism in 
the laboratory and clinically. Three of these, viz. Herba epimedii (淫羊藿, Yín Yáng Huò), Fructus ligustri lucidi (女貞子, Nǚ Zhēn Zi), 
and Fructus psoraleae (補骨脂, Bǔ Gǔ Zhī) were chosen to form a herbal formula, ELP. ELP was tested on in vitro platforms and was 
shown to have both osteoblastic and anti‑osteoclastic action. ELP tested on ovariectomized rats also showed BMD protection. ELP 
was then put on a placebo‑controlled randomized clinical trial. BMD protection was obvious among those women with the onset of 
menopause beyond 10 years (P < 0.05). A general protective trend was observed among all women under trial (P > 0.05). Although a 
thorough literature review on the herbal treatment effects did not give convincing answers to the use of Chinese herbs in osteoporosis, 
our study supports more research and trials in this area, while we are looking for safe and effective agents to keep the bone metabolism 
in a balanced state.
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breakdown are kept at a harmonized speed, so that there is good 
balance between the two mechanisms that are kept at a dynamic 
state. The balance is affected most commonly when the breakdown 
mechanism supersedes the restoration process and the causes 
behind could be aging, nutritional, disuse, vitamin D deficiency 
(no sunlight), and disease conditions. Given good health, good 
nutrition, and freedom from major diseases, aging becomes the 
most unquestionable cause of bone loss.[1]
There are many ways to assess the physiological state of bone in 
the living individual, including clinical tests, imaging, and biochemi‑
cal tests, of which imaging to detect the bone mineral density (BMD) 
has become the most accepted simple and reliable investigation.[2]
There have been many studies on the BMD of patients of 
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different ages, and it has been confirmed that BMD declines with 
aging, and for women, menopause is accompanied with a rapid 
drop of BMD. When the sudden drop of BMD associated with 
menopause became solidly known, explorations on the preven‑
tion of the drop started. Exercises and nutritional considerations 
could well be effective means to prevent the decline in BMD and 
to maintain a balance. Nevertheless, clinicians and their clients are 
not satisfied with a slow maintenance. They want an immediate 
rise of BMD. Starting with hormonal replacement which appears 
logical because menopause is associated with a decline in female 
hormones, other pharmaceutical agents have come to market with 
increasing efficacy on BMD promotion.[3]
There are incidents of bone fractures at the vulnerable 
weight‑bearing sites, particularly during accidents, when the bones 
have become weak because of low BMD (osteopenia and osteo‑
porosis). The increased risks of fracture when the bone becomes 
osteoporotic appear logical since the weak bone is certainly less 
resistant to stress and bending forces. All aging people have great 
fear against fractures. The fear thus becomes transferred to a fear 
about osteoporosis. The transfer of fear could have been logical 
but might not be fair because there must be many other risk factors 
leading to fractures, apart from a low BMD. Other risk factors 
are the accident itself and the factors leading to the accident such 
as dementia, frailty, neurological symptoms, visual problems, 
medications, etc., led pharmaceuticals companies on an active 
pursuit for BMD raising drugs agents to artificially raise the BMD.
Osteoporosis has become a major health issue worldwide. It is 
defined as a condition characterized by low BMD and micro‑archi‑
tectural deterioration of bone tissues leading to enhanced bone fra‑
gility and a consequent increase in fracture risk.[4] Postmenopausal 
osteoporosis typically affects women within 10‑15 years after 
menopause. It is complicated with fractures occurring at sites that 
contain relatively large amounts of cancellous bone. The prevalence 
of osteoporotic fracture is extremely high. In the United States, for 
women at 50 years of age, the lifetime risk is 17.5% for the hip 
fracture, 16% for vertebral fracture, and 16% for Colles’ fracture. 
Approximately 50% of 70‑year‑old women or 40% women after 
the menopause experience one or more fractures.[5,6]
In China, epidemiological studies have shown that the inci‑
dence of osteoporosis in the population over 40 years of age is 
16.1%, over 60 years of age is 22.6%, and over 80 years of age, 
it is as high as 50%. Osteoporosis in the spine not only leads of 
fractures, but would also produce pain and back deformities, which 
seriously affect the patients’ quality of life.[7]
Estrogen plays an important role in coordinating the activities 
of the bone‑forming osteoblasts and bone‑resorbing osteoclasts in 
bone homeostasis. Ovarian hormonal deficiency is one of the most 
important factors leading to postmenopausal osteoporosis, which has 
made hormonal replacement therapy popular in the early days for the 
prevention of bone loss in postmenopausal women. However, treat‑
ment with estrogen has well‑known side effects such as breast sore‑
ness and nausea, and in the long‑term, may lead to increased risk of 
breast and uterine cancer development and also venous thrombosis.[8,9]
Subsequently, when other therapeutic measures are developed 
to correct the deteriorating BMD, the direction is one of quick 
correction. This concept is acceptable when the loss of BMD is 
sharp and severe, under which circumstance, effective restoration 
is preferred. However, when the BMD is only starting to decline, 
there is a doubtful necessity of bringing it up quickly and artificially 
using drug treatment. It might be more favorable just to maintain 
the bone mineral contents and prevent any uncontrolled decline. 
Food supplements, therefore, could be a valuable offer.
The intention of this review is to explore the biological effects 
of the herbs used to maintain bone health, and then study the 
reported results of clinical treatment. Our own experience in the 
search for effective herbal treatment for the maintenance of bone 
health will be finally described.
PHYTOTHERAPY FOR OSTEOPOROSIS AS 
REVEALED FROM CHINESE LITERATURE
Laboratory studies
Natural herbs have been widely used in clinical practice in 
China and other countries since ancient times. Certain natural herbs 
have potential effects in promoting gonadal function and fracture 
healing, and therefore are suitable items for current research to 
counteract and prevent postmenopausal osteoporosis.
In China, bone health is considered closely related to kidney 
function. Thus, “kidney deficiency” (腎虛, Shèn Xū) is consid‑
ered the root of all pathologies related to bones and joints, which 
include arthritis and osteoporosis. Treatment accordingly follows 
the principle of strengthening the kidney function when the bones 
and joints are considered “weak”.[10]
Of the many herbs reported to be useful for kidney strength‑
ening, around 30 are popular and 6‑8 are most frequently used. 
They are: Herba epimedii (淫羊藿 Yín Yáng Huò), Fructus 
psoraleae (補骨脂 Bǔ Gǔ Zhī), Radix rehmanniae (生地黃 
Shēng Dì Huáng), Rhizoma drynariae (骨碎補 Gǔ Suì Bǔ), Herba 
cistanches (肉蓯蓉 Ròu Cōng Róng), and Cortex eucommaie 
(杜仲 Dù Zhòng).
No matter how many biologically active chemical components 
are contained in the herbs and how complex their mechanisms of 
action could be, the phytoestrogens in the herbal preparations, viz. 
certain flavones, isoflavones, flavanones, flavonols, coumestans, 
and lignans, could be playing an important role in the amelioration 
of postmenopausal bone loss.[11‑13] The effects of phytoestrogens 
have been reported in both laboratory studies and clinical trials. 
Studies in ovariectomized rats have suggested that the known 
phytoestrogens such as coumestrol, genistein, and daidzein can 
reduce bone loss.[14,15]
Phytochemical analyses have revealed that the six most com‑
monly used herbs just quoted contain more specific components 
such as icariin in H. epimedii (淫羊藿 Yín Yáng Huò) and iso‑
psoralen in F. psoraleae (補骨脂 Bǔ Gǔ Zhī). These effective 
components have estrogen‑like effects and may become new 
phytoestrogens for future research.[15]
Clinical studies
Xu, et al. reported in 2008 that 63 randomized control tri‑
als (RCTs) were conducted in China in which postmenopausal 
bone loss was treated with oral administration of herbs. Only 14 
of the trials met the criteria of RCT. Treatment duration of the 
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included trials ranged from 1 to 6 months. In 11 out of the 14 
trials, the treatment groups were treated with patent herbal for‑
mulae. There were obvious defects in the design of the clinical 
trials. Firstly, the use of blinding and stratified randomization 
according to age and length of menopause were not employed. 
Secondly, the small sample sizes in some of the trials were a matter 
of concern. Thirdly, prior drug history was not stated explicitly. 
Fourthly, reporting BMD change as mean differences with as‑
sociated standard deviations was not sufficient for data analysis. 
The authors compared the results of herbal treatment with those 
of hormonal treatment and reported that the prevention of bone 
loss at the classical regions of lumbar and femoral regions was 
about the same, and that adverse effects like uterine bleeding and 
breast pain were not objectively described. These studies could be 
further criticized because of short treatment durations.[16]
STUDIES DONE IN HONG KONG
Our laboratory is aware of the importance of osteoporosis 
related to aging. We are of the view that osteoporosis, though 
contributing toward the risks of bone fractures, might not be the 
major culprit. Hence, clinicians’ concern might not be a rapid 
boosting of the BMD, but a long‑term maintenance of the bone 
quality. In this regard, highly effective therapeutic agents that 
artificially suppress osteoclastic activities might not be the best 
choice for bone health, unless the BMD has reached a dangerously 
low level. This consideration might appear particularly logical 
when potent osteoclast antagonists, viz. the bisphosphonates, are 
showing incidents of adverse effects like odd fractures and cardiac 
complications when taken for a long duration.[17,18]
We selected three herbs classically used for “kidney insuf‑
ficiency,” for our laboratory and clinical studies.
Laboratory studies
The herbs used were H. epimedii (淫羊藿 Yín Yáng Huò), 
Fructus ligustri lucidi (女貞子 Nǚ Zhēn Zi), and F. psoraleae 
(補骨脂 Bǔ Gǔ Zhī) – ELP. They were mixed in the ratio 10:8:2, 
and were boiled, extracted, and prepared in a powder form.
ELP were first tested in the laboratory to establish the sci‑
entific evidence of their bone supportive activities. The known 
active compounds of the three herbs, ELP, are listed in Table 1. 
The anabolic effects of ELP on bone formation were evalu‑
ated using cultured rat osteoblast‑like osteosarcoma cell line 
UMR‑106 and rat mesenchymal stem cells (MSCs). To test for 
bone resorption, RAW 264.7 cell line was used to investigate 
the inhibition of osteoclast formations. A dosing effect with 
several concentrations (1 g/day, 0.5 g/day, and 0.175 g/day) 
was tested in ovariectomized, and calcium deficiency‑induced 
osteoporotic rats.[19]
RESULTS
In the in vitro studies, ELP significantly increased the prolifera‑
tion of UMR‑106 cells in a dose‑dependent manner from 50 to 400 
µg/ml [Figure 1]. For MSCs, ELP stimulated the osteogenic differ‑
entiation as indicated by the increase of bone markers such as alka‑
line phosphatase (ALP) activity and matrix calcium mineralization. 
ELP elevated the ALP activity significantly at concentrations of 
50 and 100 µg/ml [Figure 2a]. The amount of mineralization also 
increased significantly with ELP [Figure 2b]. In regards to bone 
resorption, ELP significantly inhibited osteoclast formation from 
RAW 264.7 cells upon receptor activation of nuclear factor‑kappa 
B ligand induction on the 4th day of treatment, at a concentration of 
80 and 160 µg/ml. The difference between treated and untreated 
cultures of osteoclasts reached statistical significance (P ≤ 0.05). 
The experimental data, therefore, illustrated that the formula ELP 
had positive effects on bone metabolism through a double process 
of osteoblastic promotion and osteoclastic inhibition.
In the ovariectomized, and calcium deficiency‑induced osteopo‑
rotic model, after 11 weeks of ELP treatment, it was demonstrated 
that there was preservation of BMD at the proximal femur in a 
dose‑dependent manner with a preference for higher dosages. No 
significant increase in uterine weight was observed in the ELP 
treated rats. In addition, the microarray data of kidney tissues re‑
vealed that ELP was able to down‑regulate the expression of phase 
II drug metabolizing enzymes, similar to the effects of estrogens.[19]
Clinical studies
The design of the clinical trial was of randomized, dou‑
ble‑blind, and placebo‑controlled nature. Proper ethical approval 
was obtained before starting the clinical trial and proper consent 
was given by the clients.
The inclusion criteria were: Women who experienced menopause 
for at least 1 year, with their lumbar spine BMD lower than 0.891 g/cm2, 
which indicated osteopenia. Those suffering from serious concomitant 
Figure 1. Effect of ELP water extract on the cell viability of osteoblast‑like 
UMR‑106 cells for 3 days at different concentrations. Data are the means 
(SEM; error bars) from three independent experiments in triplicate. 
*P < 0.05; **P < 0.01 for difference in percentage of live cells from 
respective baseline culture without treatment
Table 1. Known active compounds of ELP
Herbs Known active compound
Herba epimedii Icariin
Fructus ligustri lucidi Salidroside
Fructus psoraleae Psoralen, isopsoralen
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diseases and were maintained on complicated medications, and those 
suffering from psychiatric or addiction disorders were excluded.
Two hundred and twenty‑eight patients from volunteers in com‑
munity centers in Hong Kong were screened and 78 were found 
unsuitable. A total of 150 subjects were considered adequate for 
this study basing on the assumption that at least 1% difference in 
BMD could be observed between the treatment and placebo groups 
with 90% power, if the standard deviation of BMD measurements 
was 3.6%.
The subjects enrolled were randomized to either ELP (75 cas‑
es) or placebo (75 cases) group. In the ELP group, the mean 
age of subjects was 58.4 ± 3.6 years, the mean time since last 
menses was 8.1 ± 4.4 years, and the mean age of menopause 
onset was 50.4 ± 3.8 years, whereas in the control group, they 
were 58.4 ± 3.8 years, 8.4 ± 4.7 years, and 50.0 ± 4.2 years, 
respectively. There were no significant differences between the 
ELP and placebo groups in demographic and baseline BMD 
characteristics. The intention‑to‑treat (ITT) approach was ad‑
opted [Figure 3].
The primary outcome was the BMD of the lumbar spine 
assessed at baseline and 6 and 12 months after treatment, us‑
ing a Hologic type 4500 DEXA machine. Secondary end points 
included peripheral quantitative computed tomography (pQCT) 
measurements of the distal tibia and an analysis of the physical 
components of the quality of life (SF‑36 questionnaire). Only the 
four physical domains relevant to bone and joint problems were 
evaluated. Among the 150 subjects, 79 subjects (41 in the ELP 
group and 38 in the placebo group) received pQCT examination.
Adverse events (AEs) were carefully monitored and checking 
for biochemical functions of the liver and kidney was done for all 
clients before and after treatment. The resulting data were analyzed 
using to the ITT principles.
RESULTS
In the ELP group, 75 subjects completed the 12‑month clinical 
study; 74 subjects in the placebo group completed the 12‑month 
study: The mean drug compliance rates were 73.7% and 81.2% in 
the ELP and placebo groups, respectively. There were no statistical 
differences between the two groups.
Both ELP and placebo groups showed a decrease in spine BMD 
over the 12‑months treatment period (−0.31% in the ELP group 
and −0.39% in the placebo group). However, the spine BMD of 
the ELP group was increased by 0.69% in subjects with more than 
10 years duration of menopause. In contrast, the placebo group of 
the same stratum decreased by 0.61% (P = 0.067).
The hip BMD of the ELP group remained unchanged 
over 12‑month treatment, whereas the placebo group decreased 
by 0.22%. In the subjects with more than 10 years duration of 
menopause, the hip BMD increased by 0.21%, compared with a 
decrease of 0.52% in the placebo group [Table 2].
After 12 months of treatment with the herbal preparation, the 
distal tibia pQCT decreased by 2.43% in the ELP group compared 
with 3.67% in the placebo group (P = 0.052). The tibia (T33%) 
strength–strain index (SSI) was increased by 1.94% in the ELP 
group compared with 0.33% in the placebo group (P = 0.047) 
[Table 3].[20]
Comparison of QOL
SF‑36 questionnaire showed remarkable improvement in 
Figure 2b. Dose effect of ELP on the matrix mineralization in rat MSCs 
on day 7 (***P < 0.001)
Figure 3. Flowchart for inclusion of patients
Figure 2a. Dose effect of ELP on the ALP activity in rat MSCs on day 7
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physical function and physical role in the ELP group compared 
with the baseline, but failed to reach dominance over the placebo 
group [Figure 4]. AEs were insignificant.
DISCUSSION
Traditional Chinese Medicine is built on the principle of main‑
taining physiological harmony. Since specific pathological changes 
are unknown to the ancient experts, Chinese medicine aims, not 
at specific targets, but at the maintenance of normal “internal bal‑
ance.” The well‑known theory of “yin and yang” is a philosophical 
expression of excess and deficiency which need to be balanced. In 
the case of osteoporosis prevention, when Chinese herbs are used, 
the rationale would be one of balanced bone formation and bone 
resorption. On a cellular level, it would be a balance between os‑
teoblastic construction and osteoclastic destruction. The expected 
responses would be a steady BMD, and not a rapidly increasing one. 
However, when we design a protocol for an osteoporosis preven‑
tion trial using Chinese herbs, the end point would best follow the 
current trend which relies on the BMD levels.
In Traditional Chinese Medicine, osteoporosis has not been 
described. However, syndromes with low back pain, back deformi‑
ties, loosening teeth, etc., which appear in classical records, could 
be the manifestations of osteoporosis. Chinese herbs have been 
widely used in orthopedic practice and many of their therapeutic 
effects on skeletal problems and fractures have been reported.[21‑23] 
In our study, we have selected three common herbs from the pool of 
Chinese medicine, which are known to be good for bone health, to 
form a cocktail. The three herbs have been used both as a traditional 
drug and as food items for “kidney strengthening” in soup making 
for normal meals. The safety of these herbs has been proven in our 
clinical trial, as no significant adverse effects are demonstrated.
The best results were shown among the group of clients 
who had experienced menopause for over 10 years. This group 
of patients when treated with ELP for 12 months showed better 
results than the placebo group. Other women with shorter periods 
of menopause also showed a better trend of bone preservation 
which, however, was statistically insignificant. If BMD represents 
the standard changes in the bone density, pQCT which assesses 
the distal tibia is more sensitive to early influences and less potent 
effects. In our clinical trial, the supportive effects of ELP on the 
distal tibia were shown and statistical significance was reached.
Although there are many reports in China endorsing the 
therapeutic value of various herbs originally used as “kidney 
tonics” against “kidney deficiencies,” the claims have not been 
based on reliable clinical trials. Since ELP is not aiming at any 
specific target of bone metabolism, its efficacy would be inferior 
to target‑oriented pharmaceuticals. A longer period of observa‑
tion and a larger sample size might be mandatory for a proper 
biostatistical revelation of the results of treatment. ELP might be 
considered capable of providing additional support on top of the 
essential needs against osteoporosis, like vitamin D and calcium. 
Herbal treatments in Chinese medicine are well known to be work‑
ing slowly and non‑specifically. Although the mechanism of action 
of the three herbs in EPL has been shown in our laboratory to be 
both pro‑osteogenic and anti‑resorptive, more explorations on 
the mode of action of the herbs need to be done. We also need to 
know whether the support on the BMD is through a cellular level, 
or indirectly via an increased absorption or decreased excretion 
Table 2. Comparison of BMD changes
Item ELP (75 cases) Placebo (74 cases) P value
Spine
Baseline (g/cm2) 0.7994±0.1089 0.7949±0.1011 0.794
Change from 
baseline (%)
Month 6 −0.01 0.35
Month 12 −0.31 −0.39
Menopausal 
duration >10 years
Month 6 0.13 0.18
Month 12 0.69 −0.61 0.067
Hip
Baseline (g/cm2) 0.7573±0.0736 0.7592±0.0904 0.885
Change from 
baseline (%)
Month 6 0.19 0.44
Month 12 0.03 −0.22
Menopausal 
duration >10 years
Month 6 0.63 0.30
Month 12 0.21 −0.52 0.159
BMD: bone mineral density
Table 3. Annual changes of BMD at different anatomic sites measured 
by pQCT (%)






Total Cortical Total Trabecular
ELP 41 6.65 3.57 −2.43 6.15 1.94
Placebo 38 2.03 −0.28 −3.67 12.17 0.33
P value 0.724 0.322 0.052 0.525 0.047
BMD: bone mineral density; SSI: strength strain index; pQCT: peripheral 
quantitative computed tomography
Figure 4. Changes in the four subscales of the SF‑36 after 12 months 
of treatment
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of calcium, and whether vitamin D is involved.
An evidence‑based methodology has been followed in the 
development of ELP as an effective agent for the prevention of 
osteoporosis, not for active treatment. Long‑term effects and safety 
are of more importance than rapid rises in BMD and in preventive 
therapy. In prevention, evidences of steady maintenance could be 
more desirable than specific responses, and multiple foci of atten‑
tion could be better alternatives to specific, single target therapy.
Some chemicals that the ELP formula contains are already 
known.[24] Chemists and pharmacologists could further fraction‑
ate the extracts to work out the groups of chemicals that are 
mainly responsible for the bioactivities and are responsible for 
the anti‑osteoporotic effects.
CONCLUSION
Traditional practitioners emphasize on the clinical responses 
of individual patients. They are not totally supportive of RCTs 
which insist on group analysis and uniform treatment. Indeed, 
traditional practitioners prefer treating their patients accord‑
ing to their syndrome presentation, i.e. the “clinical pattern” 
apparent to the attending clinician. They are looking forward 
to a balancing effect rather than an abrupt effective control of 
the problem. In the situation of osteoporosis, current clinical 
practice has chosen BMD measurement as a convenient tool of 
assessment. The time taken to achieve an observable improve‑
ment in BMD while using herbal supplement is expected to be 
longer and the intensity of improvement is also expected to be 
milder since the nature of treatment is not specific.
Modern pharmaceuticals aim at quick and specific responses. The 
popular pharmaceutical agents elevate BMD within a short period for 
the need of those people at high risk. However, a proportion might 
respond too well to give rise to overhardening of cortical compo‑
nents of the long bone, which might lead to odd fractures at unusual 
sites.[17,18] On the other hand, herbal treatment is supportive and slow. 
It offers prevention and maintenance rather than over‑active treatment.
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